SMALL LYMPHOCYTIC LYMPHOMA

This study tests a combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab as the first treatment for people with chronic lymphocytic leukemia (CLL) who have a specific genetic marker (mutated IGHV) and no deletion in chromosome 17. The goal is to see if this dr…

This study tests whether people with chronic lymphocytic leukemia (CLL) can safely start venetoclax faster than the usual 5-week schedule. About 40 patients with new or returning CLL will take venetoclax daily with a quicker dose increase. The goal is to see if this faster approa…

This study tests whether adding a newer drug (venetoclax) to the standard two-drug therapy (ibrutinib plus obinutuzumab) works better for older adults (65+) with untreated chronic lymphocytic leukemia (CLL). About 465 participants will receive either the standard two-drug combo o…

This study tests a new approach for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Instead of taking the drugs acalabrutinib and obinutuzumab continuously, treatment stops once the cancer responds deeply (no detectable cancer cells). Participa…

This study tests whether adding a third drug, venetoclax, to the standard two-drug combination of ibrutinib and obinutuzumab can help younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 720 participants will receive either…

This study tests whether combining two targeted drugs, venetoclax and ibrutinib, can better control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It includes 234 patients whose cancer has returned or is hard to treat, as well as some untreated high-risk …

This study tests a combination of two drugs, tafasitamab and zanubrutinib, in people newly diagnosed with CLL or SLL. The goal is to see if this combination can kill more cancer cells than either drug alone. About 26 adults will take part, and researchers will measure how many ac…

This study compares a new oral drug, nemtabrutinib, against standard chemotherapy combinations for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a specific genetic change (TP53 mutation). About 300 particip…

This study tested a combination of two drugs, ibrutinib and fludarabine, in 29 people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants took ibrutinib daily and received fludarabine for a short time. The goal was to see how many patients achi…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have returned or not responded to prior treatments. The drug delivers radiation directly to cancer cells. A…

This study tests an experimental drug called epcoritamab, given alone or with other medicines, in about 195 people whose chronic lymphocytic leukemia (CLL) or Richter's syndrome has stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink o…

This phase 3 study tests whether the targeted drug zanubrutinib works better than the standard combination of bendamustine and rituximab for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 590 participants who cannot take stronger chemo wil…

This study tests whether adding a new targeted drug, pirtobrutinib, to standard therapy (venetoclax and rituximab) can help people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received treatment. About 600 participants will receive …

This study tests a combination of two drugs, pirtobrutinib and venetoclax, for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this treatment can reduce cancer to very low levels, measured by a sensitive blood test. The leng…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing types of B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with various subtypes, including follicular lymphoma and chro…

This study looks at whether giving vitamin D supplements to cancer patients who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 adults with certain types of lymphoma or leukemia are taking part. Researchers are comparing those who …

This study tests whether the drug lenalidomide, combined with a vaccine, can help the immune system fight early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people with high-risk genetic features. About 49 participants will receive the treatment…

This study tests a combination of three drugs (acalabrutinib, umbralisib, and ublituximab) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see how many patients achieve complete remission after 24 cycles of treatment. The study incl…

This study compares a new oral drug, LOXO-305, to two standard treatment combinations (idelalisib plus rituximab or bendamustine plus rituximab) in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with a BTK inhibito…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Over 500 participants were randomly assigned to…

This study tests a new treatment called rapcabtagene autoleucel (YTB323) for several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. About 217 adults will receive this ther…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This study tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in about 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the co…

This study tests whether a daily pill called pirtobrutinib works better than the standard combination of bendamustine and rituximab for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not yet been treated. About 309 participants will be randomly as…

This study tests an experimental drug called BGB-11417 in 100 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. The goal is to see if the drug can shrink or eliminate cancer cells. Particip…

This study tests a new drug called acalabrutinib for people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal is to see if the drug is safe and can shrink or control the cancer. Participants take the drug by mouth, and the study tracks side effects and ho…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study tests an experimental drug called epcoritamab in Japanese adults whose B-cell lymphoma has come back or not responded to treatment. The trial has two parts: first, finding a safe dose, and second, checking how well the drug works alone or with other treatments. About 7…

This early-phase study tests an experimental drug called ABBV-453 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments. Participants first receive a standard antibody (obinutuzum…

This early-phase study tests an experimental therapy called NKX019, made from donor immune cells (natural killer cells) engineered to target and kill cancer cells. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to othe…